focalinterest.net

Tag: Cancer Care

  • HSPA8, LMNA, and SERPINH1 were linked to chondrosarcoma

    What the study found

    The study identified three potential biomarkers for chondrosarcoma: HSPA8, LMNA, and SERPINH1. Their higher expression was confirmed in chondrosarcoma patients, and the authors report that these markers may be linked to angiogenesis, the formation of new blood vessels, and the integrated stress response, a cellular stress-response pathway.

    Why the authors say this matters

    The authors conclude that HSPA8, LMNA, and SERPINH1 might offer novel insights for developing targeted therapies for chondrosarcoma associated with angiogenesis and the integrated stress response.

    What the researchers tested

    The researchers analyzed chondrosarcoma data from the GEO database using differential expression analysis, WGCNA, expression assessment, enrichment analysis, regulatory network analysis, compound prediction, molecular docking, pseudo-time analysis, and cell communication analysis. They also used RT-qPCR to confirm biomarker expression levels and examined single-cell RNA sequencing data from GSE184118 to identify key cells.

    What worked and what didn't

    Three biomarkers, HSPA8, LMNA, and SERPINH1, were identified and their expression trends were consistent across the GSE30835 and GSE22855 datasets. The abstract also reports enrichment in pathways related to protein degradation, relationships with 9 transcription factors, 69 microRNAs, and 78 long non-coding RNAs, stable binding affinity with adenosine diphosphate and lonafarnib, and stronger interactions between stromal cells and chondroid cluster 1. RT-qPCR confirmed higher expression of all three biomarkers in chondrosarcoma patients.

    What to keep in mind

    The abstract does not describe detailed study limitations. The findings are based on dataset analyses and validation described in the abstract, so the scope is limited to the data and methods reported there.

    • Three potential biomarkers were identified: HSPA8, LMNA, and SERPINH1.
    • Their expression trends were consistent across two GEO datasets, GSE30835 and GSE22855.
    • RT-qPCR confirmed higher expression of HSPA8, LMNA, and SERPINH1 in chondrosarcoma patients.
    • The study reports links between the biomarkers and angiogenesis, the integrated stress response, and protein degradation pathways.
    • Single-cell analysis showed a correlation between biomarker expression and stromal cell differentiation status.

  • Nuclear shape changes track recurrence in chordoma

    What the study found

    The study found that quantitative nuclear morphometry, a way of measuring cell nucleus size and shape, captured changes linked to recurrence in chordoma. These changes aligned with immunophenotype and genomic profiling.

    Why the authors say this matters

    The authors conclude that this approach may provide a quantitative framework for future digital pathology or AI-based analysis, pending validation in larger cohorts. They also note that prognostic biomarkers for recurrence in chordoma are limited.

    What the researchers tested

    The researchers analyzed 26 specimens from 12 adults, including 8 with non-recurrent tumors and 4 with multiple long-term recurrences and metastases over 7 to 16 years. They used whole-exome sequencing, immunohistochemistry, and nuclear morphometry.

    What worked and what didn't

    Imaging studies and routine histology showed no consistent differences between the two groups. Morphometry showed substantial variation among non-recurrent tumors and significant nuclear remodeling across recurrences, with increased nuclear size, asymmetry, and altered shape; recurrent samples also showed higher proliferation and decreased lamin A/C expression. Tumor mutational burden was low overall, varied by patient and timepoint, and tended to be higher in recurrent cases.

    What to keep in mind

    The study was based on a small sample of 12 adults and 26 specimens. The abstract says the findings need validation in larger cohorts, and it does not describe additional limitations.

    • Quantitative nuclear morphometry tracked recurrence-associated changes in chordoma.
    • Routine histology and imaging did not show consistent group differences.
    • Recurrent tumors showed larger, more asymmetric nuclei with altered shape.
    • Primary tumors from patients who later recurred had smaller, more asymmetric, and denser nuclei.
    • Recurrent samples showed higher proliferation and decreased lamin A/C expression.
    • Tumor mutational burden was low overall but tended to be higher in recurrent cases.

  • Mandibular FUS::TFCP2-positive rhabdomyosarcoma resisted chemotherapy

    What the study found

    The case described an 11-year-old boy with a rare type of rhabdomyosarcoma, a cancer that forms in muscle tissue, in the mandible (jawbone). The tumor had a FUS::TFCP2 fusion gene, and it did not respond well to standard chemotherapy.

    Why the authors say this matters

    The authors conclude that early pathological diagnosis and prompt surgical intervention are crucial for FUS::TFCP2 fusion-positive rhabdomyosarcoma because the tumor is chemoresistant, meaning it resists conventional chemotherapy.

    What the researchers tested

    The researchers reported a single pediatric case of mandibular rhabdomyosarcoma. The child first received standard induction chemotherapy for rhabdomyosarcoma at a referring hospital, then underwent radical resection with segmental mandibulectomy and reconstruction using a rectus abdominis free flap.

    What worked and what didn't

    Standard induction chemotherapy was ineffective. After surgery, histological examination showed a viable tumor with minimal response to chemotherapy, and the patient remained disease-free for 18 months.

    What to keep in mind

    This is a single case report, so the findings are limited to one patient. The abstract does not describe broader treatment comparisons or an established optimal treatment strategy for this subtype.

    • The report describes an 11-year-old boy with mandibular rhabdomyosarcoma carrying a FUS::TFCP2 fusion gene.
    • Standard induction chemotherapy for rhabdomyosarcoma was ineffective in this case.
    • Radical surgery included segmental mandibulectomy and reconstruction with a rectus abdominis free flap.
    • Pathology after surgery showed a viable tumor with minimal chemotherapy response.
    • The patient remained disease-free for 18 months after surgery.

  • Engagement with iFOCUS varied and was linked to dropout

    What the study found

    The study found that engagement with the iFOCUS web-based self-directed psychoeducational program varied, and that lower engagement at the start was associated with greater odds of dropout. It also found that engagement decreased as dyads progressed through the program.

    Why the authors say this matters

    The authors conclude that assessing engagement in digital interventions may be important. The study suggests that multiple measures of engagement can provide additional insights into how people use these programs.

    What the researchers tested

    The researchers examined iFOCUS, a four-session digital self-managed 12-week intervention for dyads, meaning advanced cancer patients and their informal caregivers, in six European countries as part of a randomized controlled trial. They used process evaluation data from 121 dyads to study engagement, dropout, patient and caregiver characteristics, post-intervention outcomes, and participants' evaluation of the intervention.

    What worked and what didn't

    Lower engagement at the outset was associated with greater odds of dropout. Patient education level and caregivers' baseline emotional function, self-efficacy, dyadic coping, and knowledge of cancer were associated with engagement, but there was no consistent evidence that engagement was associated with outcomes or with evaluation of the intervention.

    What to keep in mind

    The abstract reports inconsistencies in the extent and nature of the associations found. It also says there was more evidence that baseline characteristics affected engagement than evidence that engagement affected outcomes.

    • iFOCUS was a four-session, 12-week digital self-managed program for advanced cancer patient-caregiver dyads.
    • The program showed no effects on outcomes in the main trial.
    • Lower engagement at the beginning was linked to higher odds of dropout.
    • Engagement declined as dyads moved through the program.
    • Several patient and caregiver baseline characteristics were associated with engagement.
    • There was no consistent evidence that engagement was tied to outcomes or intervention evaluation.

  • MRI-based model assessed sarcoma grade and Ki-67 expression

    What the study found

    The study found that an automated MRI-based clinical-radiomics model may assess soft tissue sarcoma grade and Ki-67 expression, which are pathological measures used to describe tumor aggressiveness and cell proliferation. It also found that the model may improve the diagnostic performance of less-experienced radiologists.

    Why the authors say this matters

    The authors say this matters because histological grade and Ki-67 expression are prognostic risk factors in soft tissue sarcoma, and these assessments usually require biopsy, which is invasive and may be affected by tumor heterogeneity. The study suggests that an MRI-based approach could provide a noninvasive alternative for assessment.

    What the researchers tested

    The researchers conducted a retrospective study of 186 patients with pathologically confirmed soft tissue sarcoma from three hospitals. They developed an automatic segmentation model and compared it with manual segmentations, then built clinical-imaging signature models using structural MRI radiomics, structural MRI plus apparent diffusion coefficient (ADC) radiomics, and those features combined with clinical information and MRI semantic features.

    What worked and what didn't

    The segmentation model showed good performance, with Dice coefficients of 0.80 for extremity cases and 0.73 for trunk cases. In validation, the best model for grade was the logistic regression clinical-imaging signature model, and the best model for Ki-67 expression was the support vector machine model, with AUCs of 0.846 and 0.742, respectively. Using the model improved diagnostic performance for the two less-experienced radiologists, but the abstract does not report a comparable improvement for the most experienced radiologist.

    What to keep in mind

    The study was retrospective and included 186 patients, so the findings are based on a specific multicenter sample. The abstract does not describe limitations beyond the reported validation design, and it does not state how the model would perform outside the studied hospitals or in other patient groups.

    • The study evaluated an automated MRI-based clinical-radiomics pipeline for soft tissue sarcoma grade and Ki-67 expression.
    • Soft tissue sarcoma grade and Ki-67 expression are described as prognostic risk factors and usually require biopsy.
    • The segmentation model achieved Dice coefficients of 0.80 in extremity cases and 0.73 in trunk cases.
    • The best validation AUCs were 0.846 for grade and 0.742 for Ki-67 expression.
    • Model use improved diagnostic performance for the two less-experienced radiologists.

  • En bloc resection preserved function in proximal fibula GCT

    What the study found

    The study found that en bloc resection of proximal fibular giant cell tumour, together with preservation of the common peroneal nerve and reattachment of the lateral stabilizers, was followed by good oncological and functional outcomes in skeletally immature patients. Most patients recovered common peroneal nerve function, and no tumour recurrences were reported at 12 months.

    Why the authors say this matters

    The authors conclude that this approach may provide excellent oncological control and functional outcomes in skeletally immature patients with proximal fibula giant cell tumour and preoperative common peroneal nerve neuropraxia. In this context, common peroneal nerve neuropraxia means temporary weakness or loss of function of the nerve around the knee.

    What the researchers tested

    The researchers reviewed 20 skeletally immature patients aged 18 years or younger with histologically confirmed proximal fibula giant cell tumour and preoperative common peroneal nerve neuropraxia. All were treated between September 2023 and August 2024 with en bloc (Malawer type I) resection and reattachment of the lateral collateral ligament and biceps femoris, and followed for at least 12 months.

    What worked and what didn't

    All patients had negative surgical margins, and the mean operative time was 72 minutes. At 12 months, 17 patients had complete common peroneal nerve recovery and 3 had partial recovery; there were no persistent palsies and no recurrences. Knee stability was good in 17 knees, while 3 had grade I varus laxity, and complications included two superficial infections and one wound debridement.

    What to keep in mind

    This was a retrospective case series with 20 patients and one-year follow-up, so the evidence is limited to this small group and time period. The abstract does not describe a comparison group, and longer-term outcomes are not provided.

    • 20 skeletally immature patients with proximal fibula giant cell tumour were treated with en bloc resection.
    • 17 patients had complete common peroneal nerve recovery by 12 months; 3 had partial recovery.
    • No tumour recurrences or persistent palsies were reported at 12 months.
    • Most knees were stable after surgery, but 3 showed grade I varus laxity.
    • Complications included two superficial infections and one wound debridement.

  • Periocular collagenous fibroma with bone was benign

    What the study found

    The authors report a rare benign soft-tissue tumor called collagenous fibroma in the periocular region, meaning the area around the eye, with metaplastic ossification, or bone formation within the tumor. The lesion could resemble other fibrous or osseous tumors on imaging.

    Why the authors say this matters

    The authors conclude that recognizing this benign tumor is important because it can be confused with more aggressive lesions. They say this may help avoid diagnostic confusion and unnecessary aggressive management of periocular lesions.

    What the researchers tested

    The researchers described a single case of a 49-year-old woman with a small, firm mass in the lateral eyebrow region. She underwent magnetic resonance imaging and histopathologic examination after complete local excision.

    What worked and what didn't

    Magnetic resonance imaging showed a well-circumscribed lesion with low signal intensity, which raised concern for other fibrous or osseous tumors. Histopathology showed a hypocellular, collagen-rich stroma with sparse spindle-to-stellate fibroblastic cells and discrete islands of mature lamellar bone, consistent with collagenous fibroma with metaplastic ossification, and complete local excision was curative with no recurrence.

    What to keep in mind

    This is a single case report, so the findings are limited to one patient. The abstract does not describe longer follow-up beyond no evidence of recurrence after excision.

    • The case involved a rare collagenous fibroma in the periocular region.
    • The tumor contained metaplastic ossification, meaning bone formed inside the lesion.
    • Imaging suggested a possible fibrous or osseous tumor before diagnosis.
    • Microscopy confirmed a collagen-rich, low-cellularity tumor with mature bone islands.
    • Complete local excision was curative, with no recurrence reported.

  • Middle lobe torsion after lobectomy required rapid diagnosis and tailored anesthesia

    What the study found

    The report describes two cases of right middle lobe torsion, a twisting of a lung lobe, after right upper lobectomy. In both cases, persistent postoperative atelectasis, or collapse of part of the lung, led to repeated bronchoscopy and contrast-enhanced computed tomography, which supported early diagnosis and timely surgery.

    Why the authors say this matters

    The authors conclude that middle lobe torsion is an uncommon but potentially life-threatening complication and that it should be considered when atelectasis persists despite preserved oxygenation. They also suggest that systematic imaging and close multidisciplinary coordination are important for optimizing perioperative outcomes in this rare condition.

    What the researchers tested

    The researchers reported two case reports of postoperative right middle lobe torsion after right upper lobectomy. They describe anesthetic planning for reoperation, including lung isolation with double-lumen tubes, attention to possible airway mucosal edema, and hemodynamic monitoring during release of the torsion.

    What worked and what didn't

    In the first case, the torsion was irreversible and the lobe had compromised perfusion, so middle lobectomy was needed. In the second case, preserved parenchymal enhancement on imaging allowed detorsion with lobar fixation. Both patients maintained acceptable oxygenation and stable hemodynamics during anesthesia, and there was no evidence of reperfusion-related instability.

    What to keep in mind

    This is a report of only two cases, so the findings are limited to those experiences. The abstract does not describe comparative data, and it does not provide broader estimates of how often these management strategies succeed beyond these patients.

    • Two cases of right middle lobe torsion occurred after right upper lobectomy.
    • Persistent postoperative atelectasis led to repeated bronchoscopy and contrast-enhanced computed tomography.
    • One case required middle lobectomy because the torsion was irreversible and perfusion was compromised.
    • The other case was managed with detorsion and lobar fixation after preserved enhancement was seen.
    • Both patients had acceptable oxygenation and stable hemodynamics during anesthesia.

  • Rare myoepithelial tumor carried EWSR1-PBX3 fusion

    What the study found

    The report describes a rare myoepithelial tumor, a heterogeneous tumor type that can arise in different tissues, in the rib and nearby soft tissue. The tumor was found to carry an EWSR1-PBX3 fusion and rearrangement.

    Why the authors say this matters

    The authors conclude that finding EWSR1-PBX3 fusion and rearrangement in myoepithelial tumors of bone and soft tissue is diagnostically significant. They say molecular testing is critical when clinicians need to distinguish this tumor from synovial sarcoma and other closely related entities.

    What the researchers tested

    The researchers reported a single case of a 52-year-old man with worsening low back pain. Imaging showed osteolytic destruction of the left twelfth rib with an associated soft-tissue mass, histopathology examined the tumor cells, immunohistochemistry tested markers including S-100, EMA, SMA, calponin, and cytokeratin, and next-generation sequencing was used to look for genetic changes.

    What worked and what didn't

    The tumor showed spindle and oval cells with mild atypia and was positive for S-100, EMA, SMA, and calponin, but negative for cytokeratin. Next-generation sequencing verified the presence of EWSR1-PBX3 fusion and rearrangement. After surgery and postoperative radiotherapy, the patient remained disease-free for 2 years.

    What to keep in mind

    This is a single case report, so the findings apply only to this patient and this tumor type as described here. The abstract does not provide broader frequency estimates or detailed limitations beyond noting the rarity of the entity.

    • The case involved a myoepithelial tumor in the left twelfth rib and surrounding soft tissue.
    • The tumor had an EWSR1-PBX3 fusion and rearrangement confirmed by next-generation sequencing.
    • Immunohistochemistry was positive for S-100, EMA, SMA, and calponin, and negative for cytokeratin.
    • The authors say the genetic finding is diagnostically significant for this tumor type.
    • The patient remained disease-free for 2 years after surgery and postoperative radiotherapy.

  • Combination therapy produced a temporary response in metastatic DDCS

    What the study found

    The authors report a 72-year-old man with metastatic de-differentiated chondrosarcoma who had a significant clinical response to the combination of pembrolizumab, an immune checkpoint inhibitor, and pazopanib, a multi-targeted tyrosine kinase inhibitor. The response was temporary, with later disease progression.

    Why the authors say this matters

    The authors conclude that this case is a valuable example of promising emerging systemic therapies for advanced de-differentiated chondrosarcoma, a rare cancer with few proven treatment options. They note that standard care currently lacks a repertoire of effective therapies.

    What the researchers tested

    This was a single case report of one patient with metastatic de-differentiated chondrosarcoma. The report describes surgery, adjuvant radiotherapy, genetic sequencing, imaging with FDG PET-CT, and later treatment with vismodegib followed by pembrolizumab plus pazopanib.

    What worked and what didn't

    After diagnosis, lung metastases appeared and vismodegib had progressive disease as the best response. Later, pembrolizumab plus pazopanib was associated with a significant reduction in the size of the lung metastases and a progression-free period of 6 months, but the disease progressed again and treatment was stopped.

    What to keep in mind

    This is a single-patient report, so the findings cannot be generalized from this case alone. The abstract does not describe a control group, and the response was complicated by hepatotoxicity that improved after pazopanib dose reduction.

    • A 72-year-old man with metastatic de-differentiated chondrosarcoma had a significant response to pembrolizumab plus pazopanib.
    • The response lasted 6 months before later relapse and progression.
    • Vismodegib did not help; the best response was progressive disease.
    • Treatment was complicated by hepatotoxicity that resolved after lowering the pazopanib dose.
    • The authors present the case as an example of emerging systemic therapy options for advanced de-differentiated chondrosarcoma.